Raltegravir (CAS 518048-05-0)

Raltegravir, also referred to as MK-0518, is an antiretroviral compound. As a human immunodeficiency virus (HIV) integrase strand transfer inhibitor (HIV-1 INSTI), raltegravir displays potent antiviral activity against HIV-1. By binding to and inhibiting the action of integrase, an essential HIV enzyme responsible for incorporating viral genetic material into the host cell′s genetic material, raltegravir effectively blocks HIV replication. This potent HIV-1 integrase inhibitor exhibits significant efficacy in inhibiting HIV-1 both in vitro and against HIV-2 in CEMx174 cells. While it does weakly inhibit hepatic cytochrome P450 activity, raltegravir is primarily recognized for its ability to effectively attenuate viral replication and combat the spread of HIV. Furthermore, raltegravir showcases its potency by sensitizing S217Q PFV IN to the same extent as the WT enzyme. In the context of acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, raltegravir efficiently inhibits the replication of SIVmac251, a simian immunodeficiency virus strain.